OBJECTIVES: To conduct a cost-effectiveness analysis (CEA) of continuous remote monitoring (RM) of heart failure (HF) patients with cardiac electronic implantable device. METHODS: A cost-effectiveness analysis was conducted for a 10-year time horizon, from third-party–payer perspective only including the direct healthcare costs. A Markov model was adapted with four health states for two alternatives: (1) continuous RM with data transmission on a daily basis, (2) conventional, regular in-office follow-up (CFU). The costing estimates are based on Hungarian data. The effectiveness is measured as the number of life years saved. The input data of effectiveness are based on randomised clinical trials and data provision of the Hungarian National Health Insurance Fund Administration.  RESULTS: As a result of CEA, 652 life years can be saved in a 10-year time horizon in a patient cohort (N=100). The ICER value is 1.78 million HUF (≈ 5,730 EUR) per life year saved. To our estimation 4,500-5,600 HF patients could be continuously remote monitored by the end of the 5th year with a gradual inclusion of patients. Taking into account the mortality of both arms, under 5 years, extra 520-650 lives (among the gradually involved 4,500-5,600 patients) can be saved with using RM compared to the CFU. Both to the deterministic and probabilistic sensitivity analysis the ICER calculated is relatively robust. CONCLUSIONS: The ICER calculated is lower than the threshold of cost-effectiveness set in Hungary. The number of lives can be potentially saved is favourable, especially by the HF patient population regarding its relatively low 5-year survival rate (below 50%). The Hungarian health policy should consider the inclusion of RM into the public reimbursement system and at the same time establishing a patient registry for the remotely monitored HF patients to evaluate the long term benefits of RM.